Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Antisense oligonucleotide drug targets alpha-1-antitrypsin deficiency

Nov. 22, 2012

EMA committee recommends approval of lixisenatide

Nov. 19, 2012

Bristol-Myers Squibb gains option rights for Biocon drug

Nov. 19, 2012

AstraZeneca will not exercise the option to acquire diabetes assets from Prosidion

Nov. 16, 2012

Chong Kun Dang Pharmaceutical divulges new CETP inhibitors

Nov. 16, 2012

Bristol-Myers Squibb and AstraZeneca gain European approval for dapagliflozin

Nov. 15, 2012

Novartis discloses novel prodrugs of SGLT1/2 inhibitors

Nov. 14, 2012

NDA for nonhormonal therapy for menopausal vasomotor symptoms accepted for review by FDA

Nov. 14, 2012

Edison Pharmaceuticals commences phase IIb trial of EPI-743 in children with Leigh syndrome

Nov. 14, 2012

Preliminary clinical results presented for FG-4592 in hemodialysis patients

Nov. 14, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...